Abstract: The present invention discloses isoquinolines and 1H-2-Benzopyranes and their use in the treatment and prevention in epilepsy and other seizures. The present invention further discloses methods to screen isoquinoline- and 1H-2-Benzopyran-like molecules as pharmaceutically active compounds.

Abstract: An electron tube includes a housing that is internally held in a vacuum and has a window transmitting an electromagnetic wave, an electron emitting unit that is disposed in the housing and has a meta-surface emitting electrons in response to incidence of the electromagnetic wave, an electron multiplying unit that is disposed in the housing and multiplies the electrons emitted from the electron emitting unit, and an electron collecting unit that is disposed in the housing and collects the electrons multiplied by the electron multiplying unit. The window contains at least one selected from quartz, silicon, germanium, sapphire, zinc selenide, zinc sulfide, magnesium fluoride, lithium fluoride, barium fluoride, calcium fluoride, magnesium oxide, and calcium carbonate.

Abstract: This invention concerns a photo-cathode for a vacuum system, wherein the photo-cathode is configured for receiving electromagnetic radiation having an incoming wavelength and for emitting electrons in response thereto. The photo-cathode comprises a conducting structure having a geometry, the geometry comprising a tip section. The tip section is adapted to provide field enhancement, ?, when the conducting structure is illuminated with the electromagnetic radiation, wherein ? is greater than about 102. The photo-cathode further comprising a substrate, the substrate being or comprising a dielectric substrate, the substrate supporting the conducting structure.

Abstract: There is provided an encryption device to ensure strong security without using a random number in a white-box model. The encryption device includes: an encryption part configured to encrypt an input value using a black-box model in which input/output values are able to be recognized from the outside and an intermediate value is not able to be recognized from the outside; and a key generation part configured to encrypt the input value to the encryption part to generate a cryptographic key of the encryption part using a white-box model in which the input/output value and the intermediate value are able to be recognized from the outside.

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

Abstract: Compositions that comprise protein conjugates comprising an NTF and a nontoxic fragment of a Clostridial neurotoxin. Vectors, host cells, and methods of use and making are also described. Pharmaceutical compositions comprising the protein conjugates described herein are used to provide neuroprotection and treat neurodegenerative diseases and neuron damage amongst other things.

Abstract: Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T1 contrast enhancement (T1˜900 ms) in the rim over at least 3 weeks with clinically observable resolution.

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

Abstract: There is provided an encryption device that is secure against a side channel attack, and can suppress a processing load. The encryption device includes a data encryption part in which at least part of a plurality of round functions for successively performing encryption processing on an input value is tabulated to be encrypted using a white-box model in which input/output values of the round function is able to be recognized from the outside. Each of the round functions includes a tabulated encryption function for encrypting an input value using a black-box model in which the input/output values are able to be recognized from the outside and an intermediate value is not able to be recognized from the outside, and the encryption function is updated with a random number.

Abstract: The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.

Abstract: The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body.

Abstract: There is provided an encryption device that is secure against a side channel attack, and can suppress a processing load. The encryption device includes a data encryption part in which at least part of a plurality of round functions for successively performing encryption processing on an input value is tabulated to be encrypted using a white-box model in which input/output values of the round function is able to be recognized from the outside. Each of the round functions includes a tabulated encryption function for encrypting an input value using a black-box model in which the input/output values are able to be recognized from the outside and an intermediate value is not able to be recognized from the outside, and the encryption function is updated with a random number.

Abstract: A method is provided for calibrating a microfluidic system comprising, which method is based on using beads having a structure based on DNA origami, wherein said structure comprises a predetermined number of fluorophores. Furthermore, methods for determining the level of an antigen using microfluidics calibrated using fluorescent microbeads as provided herein. Also, methods are provided for determining the presence or state of a haematological disease by calibrated a microfluidics system.

Abstract: A multicore fiber includes: a first core having a first propagation loss of a first light beam in a mode one order higher than a mode of a second light beam that transmits information. The first propagation loss is 0.02 dB/m or more and 1 dB/m or less, in a wavelength band of light beams including the second light beam that transmit the information when a bend having a diameter of 280 mm is applied to the multicore fiber.

Abstract: There is provided an encryption device to ensure strong security without using a random number in a white-box model. The encryption device includes: an encryption part configured to encrypt an input value using a black-box model in which input/output values are able to be recognized from the outside and an intermediate value is not able to be recognized from the outside; and a key generation part configured to encrypt the input value to the encryption part to generate a cryptographic key of the encryption part using a white-box model in which the input/output value and the intermediate value are able to be recognized from the outside.

Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.

Abstract: The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body.

Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.

Abstract: There is provided an encryption device including a data encryption unit configured to conduct encryption on the basis of a white box model in which at least a part of a plurality of round functions for sequentially conducting encryption processing on an input value is tabulated, and input and output values of the round function are recognizable from an outside. The plurality of round functions each have an encryption function that is tabulated and encrypts an input value in a black box model in which input and output values are recognizable from the outside and an intermediate value is not recognizable from the outside.